- Home
- HTFL vs TARS Comparison
HTFL vs TARS Comparison
Compare HTFL & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTFL | TARS |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | 843 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HTFL | TARS |
|---|---|---|
| Price | $34.04 | $63.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $38.20 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.2M | 485.7K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $27.66 | $56.43 |
| Revenue Next Year | $23.55 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $20.13 | $38.51 |
| 52 Week High | $41.22 | $85.25 |
Technical Indicators
Market Signals| Indicator | HTFL | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 63.99 | 56.06 |
| Support Level | $32.09 | $61.24 |
| Resistance Level | $37.93 | $66.36 |
| Average True Range (ATR) | 1.88 | 2.62 |
| MACD | 0.44 | 0.53 |
| Stochastic Oscillator | 85.44 | 88.01 |
Price Performance
Historical ComparisonAbout HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.